GlassScriptPhysician profile
Rachel S Reed
NPI 1568076669
$2,672.71
in general payments reported to CMS, 2019-2025
25 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $541 · 2022: $435 · 2023: $751 · 2024: $680 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,696.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $449.36 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $308.61 | 2021-2024 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $218.99 | 2021-2024 | Farxiga |
| Travere Therapeutics, INC. | $203.00 | 2022-2025 | |
| Amgen INC. | $172.09 | 2022-2024 | Tavneos, Krystexxa |
| Fresenius USA Marketing, INC. | $115.80 | 2021-2024 | Velphoro |
| Vifor Pharma, INC. | $110.52 | 2021-2024 | Veltassa |
| Ani Pharmaceuticals, INC. | $105.71 | 2023-2024 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $102.18 | 2023-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $100.23 | 2022-2025 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $98.23 | 2023 | Gattex |
| Daiichi Sankyo INC. | $90.58 | 2021-2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $86.74 | 2024-2025 | |
| Organogenesis INC. | $82.08 | 2025 | Nushield, Puraply Wound Matrix |
| Ardelyx, INC. | $67.84 | 2023-2024 | Ibsrela |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $63.31 | 2021-2025 | |
| Novo Nordisk INC | $61.29 | 2022-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $58.55 | 2022-2025 | Benlysta, Jesduvroq |
| Opko Pharmaceuticals, LLC | $48.37 | 2021-2024 | Rayaldee |
| Recor Medical INC | $29.16 | 2024 | Paradise Renal Denervation System |
| Horizon Therapeutics Plc | $28.74 | 2023 | Krystexxa |
| Akebia Therapeutics INC | $22.02 | 2022 | |
| Amicus Therapeutics, INC. | $17.21 | 2021 | |
| Aurinia Pharma U.S., INC. | $16.93 | 2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.17 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.